{"id":"subcutaneous-azacitidine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Cytopenias"},{"rate":"5-20%","effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL1489","moleculeType":"Small molecule","molecularWeight":"244.21"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in the reactivation of silenced tumor suppressor genes, ultimately leading to the induction of apoptosis in cancer cells. Azacitidine also has immunomodulatory effects, enhancing the body's immune response against cancer cells.","oneSentence":"Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:33.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)"}]},"trialDetails":[{"nctId":"NCT07388563","phase":"PHASE1","title":"Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":20},{"nctId":"NCT07493330","phase":"PHASE1, PHASE2","title":"Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03-23","conditions":"PTCL, Refractory","enrollment":86},{"nctId":"NCT06379360","phase":"PHASE2","title":"Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-11-01","conditions":"Acute Myeloid Leukemia","enrollment":77},{"nctId":"NCT05796570","phase":"PHASE2","title":"A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies","status":"RECRUITING","sponsor":"Franziska Wachter","startDate":"2023-04-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies","enrollment":37},{"nctId":"NCT07478991","phase":"PHASE3","title":"Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2026-03","conditions":"Acute Myeloid Leukemia, Adult","enrollment":376},{"nctId":"NCT07387354","phase":"PHASE1, PHASE2","title":"Pacritinib With Aza for Upfront Myelodysplastic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2026-05","conditions":"Myelodysplastic Syndromes, MDS, Myelodysplastic Syndrome, Unclassifiable","enrollment":25},{"nctId":"NCT07283900","phase":"PHASE2","title":"Ascorbate in Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Prajwal Dhakal","startDate":"2026-03-11","conditions":"Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT04227847","phase":"PHASE1","title":"A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-07","conditions":"Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":178},{"nctId":"NCT07007312","phase":"PHASE3","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-09-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":1300},{"nctId":"NCT05735184","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2023-07-18","conditions":"Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML","enrollment":420},{"nctId":"NCT07451912","phase":"PHASE1, PHASE2","title":"Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-15","conditions":"Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML","enrollment":29},{"nctId":"NCT04771130","phase":"PHASE1, PHASE2","title":"A Study of BGB-11417 in Participants With Myeloid Malignancies","status":"RECRUITING","sponsor":"BeiGene","startDate":"2021-05-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":260},{"nctId":"NCT05520567","phase":"PHASE1, PHASE2","title":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-01-31","conditions":"Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT07283094","phase":"PHASE1","title":"FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-02-03","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT07439211","phase":"PHASE1","title":"Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2026-07","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT04263181","phase":"","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-29","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT07433023","phase":"PHASE2","title":"tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy","status":"NOT_YET_RECRUITING","sponsor":"Shirley Ryan AbilityLab","startDate":"2026-03-01","conditions":"Cerebral Palsy","enrollment":80},{"nctId":"NCT07434492","phase":"PHASE2","title":"Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy","status":"NOT_YET_RECRUITING","sponsor":"Shirley Ryan AbilityLab","startDate":"2026-03-01","conditions":"Cerebral Palsy","enrollment":60},{"nctId":"NCT07425782","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine for Consolidation Therapy in AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax","enrollment":216},{"nctId":"NCT06782542","phase":"PHASE2","title":"Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy","status":"RECRUITING","sponsor":"Justin Watts, MD","startDate":"2026-05-01","conditions":"Acute Myeloid Leukemia, IDH1 Mutation","enrollment":16},{"nctId":"NCT05428969","phase":"PHASE1, PHASE2","title":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Faron Pharmaceuticals Ltd","startDate":"2022-06-02","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes","enrollment":181},{"nctId":"NCT02677922","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-06-03","conditions":"Leukemia, Myeloid, Acute","enrollment":130},{"nctId":"NCT07407660","phase":"PHASE3","title":"Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-02-01","conditions":"Acute Myeloid Leukemia","enrollment":250},{"nctId":"NCT06465953","phase":"PHASE3","title":"Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2024-12-03","conditions":"Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)","enrollment":48},{"nctId":"NCT01515527","phase":"PHASE2","title":"Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-07","conditions":"Leukemia","enrollment":160},{"nctId":"NCT07148180","phase":"PHASE1, PHASE2","title":"A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax","status":"RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2026-02-02","conditions":"Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer","enrollment":31},{"nctId":"NCT07374029","phase":"PHASE1","title":"Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse","enrollment":30},{"nctId":"NCT07372352","phase":"PHASE2","title":"Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-15","conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":26},{"nctId":"NCT03264404","phase":"PHASE2","title":"Azacitidine and Pembrolizumab in Pancreatic Cancer","status":"COMPLETED","sponsor":"Susan E. Bates","startDate":"2017-10-01","conditions":"Pancreas Cancer","enrollment":36},{"nctId":"NCT04150029","phase":"PHASE2","title":"A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia","enrollment":90},{"nctId":"NCT05183035","phase":"PHASE3","title":"Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"PedAL BCU, LLC","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia","enrollment":98},{"nctId":"NCT07044687","phase":"PHASE4","title":"Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-24","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT05317403","phase":"PHASE1","title":"Venetoclax to Augment Epigenetic Modification and Chemotherapy","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-03-31","conditions":"Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory","enrollment":40},{"nctId":"NCT05201066","phase":"PHASE2","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-02-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":33},{"nctId":"NCT07320235","phase":"PHASE1","title":"Imetelstat Combinations in Relapsed AML","status":"RECRUITING","sponsor":"Douglas Tremblay","startDate":"2026-01","conditions":"Relapsed Acute Myeloid Leukemia","enrollment":36},{"nctId":"NCT05184842","phase":"PHASE2","title":"Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2022-03-23","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":91},{"nctId":"NCT05365035","phase":"PHASE2","title":"A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-23","conditions":"Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia","enrollment":60},{"nctId":"NCT03326310","phase":"PHASE1","title":"Selumetinib and Azacitidine in High Risk Chronic Blood Cancers","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2018-09-04","conditions":"Chronic Myeloid Leukemia, Myelofibroses","enrollment":18},{"nctId":"NCT02421939","phase":"PHASE3","title":"A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-10-20","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":371},{"nctId":"NCT04608110","phase":"PHASE1","title":"A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2020-10-30","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":40},{"nctId":"NCT06389292","phase":"PHASE3","title":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-06-11","conditions":"Acute Myeloid Leukemia","enrollment":486},{"nctId":"NCT06647862","phase":"PHASE3","title":"IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)","status":"RECRUITING","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2024-11-11","conditions":"Chronic Myelomonocytic Leukemia","enrollment":170},{"nctId":"NCT06532552","phase":"PHASE2","title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-29","conditions":"Acute Myeloid Leukemia, Adult, Newly Diagnosed","enrollment":172},{"nctId":"NCT03268954","phase":"PHASE3","title":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-11-28","conditions":"Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute","enrollment":454},{"nctId":"NCT04266795","phase":"PHASE2","title":"A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-10-13","conditions":"Acute Myeloid Leukemia (AML)","enrollment":164},{"nctId":"NCT02959437","phase":"PHASE1, PHASE2","title":"Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2017-02-27","conditions":"Solid Tumors, Advanced Malignancies, Metastatic Cancer","enrollment":70},{"nctId":"NCT04878432","phase":"PHASE2","title":"STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-17","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":39},{"nctId":"NCT04623216","phase":"PHASE1, PHASE2","title":"Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-14","conditions":"Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT04161885","phase":"PHASE3","title":"A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2020-02-26","conditions":"Acute Myeloid Leukemia (AML), Cancer","enrollment":465},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT04257448","phase":"PHASE1, PHASE2","title":"Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2020-05-25","conditions":"Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":75},{"nctId":"NCT05673057","phase":"PHASE1, PHASE2","title":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Molecular Partners AG","startDate":"2022-12-29","conditions":"Leukemia, Myeloid, Acute","enrollment":249},{"nctId":"NCT05471700","phase":"NA","title":"Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2022-09-01","conditions":"Leukemia, Myeloid, Acute","enrollment":40},{"nctId":"NCT05381038","phase":"PHASE1, PHASE2","title":"Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-02-13","conditions":"Solid Tumor, Gastrointestinal Cancer, Breast Cancer","enrollment":10},{"nctId":"NCT02752035","phase":"PHASE3","title":"A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-08-01","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation","enrollment":183},{"nctId":"NCT07159620","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Adult T-cell Leukemia/Lymphoma","enrollment":27},{"nctId":"NCT06129734","phase":"PHASE1, PHASE2","title":"Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant","status":"RECRUITING","sponsor":"Benjamin Tomlinson","startDate":"2025-07-28","conditions":"Myeloid Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06508489","phase":"PHASE1, PHASE2","title":"A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies","status":"TERMINATED","sponsor":"Sanofi","startDate":"2024-08-13","conditions":"Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT04102020","phase":"PHASE3","title":"A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-03-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT02993523","phase":"PHASE3","title":"A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2017-02-02","conditions":"Acute Myeloid Leukemia (AML)","enrollment":443},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT05144243","phase":"PHASE4","title":"Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-01-06","conditions":"Acute Myeloid Leukemia (AML)","enrollment":44},{"nctId":"NCT03843528","phase":"PHASE1","title":"Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2019-05-01","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia","enrollment":15},{"nctId":"NCT04401748","phase":"PHASE3","title":"Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-10","conditions":"Myelodysplastic Syndrome (MDS)","enrollment":531},{"nctId":"NCT06386302","phase":"NA","title":"Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-05","conditions":"AML, Acute Myeloid Leukemia","enrollment":184},{"nctId":"NCT07082452","phase":"PHASE3","title":"A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"Leukemia, B-Cell, Chronic, Leukemia","enrollment":262},{"nctId":"NCT04417517","phase":"PHASE1","title":"A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)","status":"TERMINATED","sponsor":"ALX Oncology Inc.","startDate":"2020-10-02","conditions":"Higher Risk Myelodysplastic Syndromes","enrollment":65},{"nctId":"NCT05209152","phase":"PHASE1","title":"AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia","status":"TERMINATED","sponsor":"Amgen","startDate":"2022-11-14","conditions":"Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia","enrollment":7},{"nctId":"NCT06377085","phase":"PHASE1","title":"Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy","status":"ENROLLING_BY_INVITATION","sponsor":"Shirley Ryan AbilityLab","startDate":"2025-07","conditions":"Cerebral Palsy, Contracture","enrollment":27},{"nctId":"NCT04603001","phase":"PHASE1","title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-11-19","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)","enrollment":260},{"nctId":"NCT01290302","phase":"PHASE1","title":"Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2010-11-22","conditions":"Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia","enrollment":38},{"nctId":"NCT07012447","phase":"PHASE2","title":"Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations","status":"RECRUITING","sponsor":"yuejun Liu","startDate":"2025-04-01","conditions":"Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T/Myeloid, Nos","enrollment":32},{"nctId":"NCT07007949","phase":"PHASE2","title":"a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-06-01","conditions":"Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib","enrollment":42},{"nctId":"NCT05709093","phase":"PHASE3","title":"A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"TJ Biopharma Co., Ltd.","startDate":"2023-03-30","conditions":"Myelodysplastic Syndromes(MDS)","enrollment":10},{"nctId":"NCT04742101","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2021-03-10","conditions":"Acute Myeloid Leukemia","enrollment":57},{"nctId":"NCT05609942","phase":"PHASE1","title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","status":"TERMINATED","sponsor":"Blueprint Medicines Corporation","startDate":"2023-09-25","conditions":"Advanced Systemic Mastocytosis","enrollment":9},{"nctId":"NCT05586074","phase":"PHASE3","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-03-03","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":324},{"nctId":"NCT05883956","phase":"PHASE3","title":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Australia Pharmaceutical Pty Ltd","startDate":"2023-12-20","conditions":"Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic","enrollment":13},{"nctId":"NCT06886425","phase":"NA","title":"Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2021-06-14","conditions":"Myelodysplastic Syndromes (MDS), Leukemia Acute Myeloid - AML","enrollment":70},{"nctId":"NCT04090736","phase":"PHASE3","title":"Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2019-09-24","conditions":"Leukemia, Myeloid, Acute","enrollment":302},{"nctId":"NCT04214860","phase":"PHASE1","title":"APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies","status":"COMPLETED","sponsor":"Aprea Therapeutics","startDate":"2019-12-13","conditions":"Myeloid Malignancy","enrollment":51},{"nctId":"NCT04980885","phase":"PHASE1, PHASE2","title":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2021-08-13","conditions":"Acute Myeloid Leukemia","enrollment":68},{"nctId":"NCT04900350","phase":"PHASE1, PHASE2","title":"A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2021-06-18","conditions":"Myelodysplastic Syndrome","enrollment":136},{"nctId":"NCT06150040","phase":"PHASE1, PHASE2","title":"Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]","status":"TERMINATED","sponsor":"Centre Leon Berard","startDate":"2024-09-11","conditions":"Acute Myeloid Leukemia Refractory","enrollment":1},{"nctId":"NCT05325099","phase":"PHASE1, PHASE2","title":"Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-04-18","conditions":"Acute Kidney Disease","enrollment":60},{"nctId":"NCT06158399","phase":"PHASE2","title":"AZA Combined With RCHOP in P53-mutated DLBCL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-11-22","conditions":"DLBCL - Diffuse Large B Cell Lymphoma, TP53","enrollment":52},{"nctId":"NCT06502145","phase":"PHASE1","title":"Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-01-10","conditions":"Myelodysplastic Syndromes","enrollment":12},{"nctId":"NCT06741722","phase":"PHASE2","title":"Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-10-31","conditions":"AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT02807558","phase":"PHASE2","title":"A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Syros Pharmaceuticals","startDate":"2016-09-20","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":155},{"nctId":"NCT06612944","phase":"PHASE2","title":"Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-11-12","conditions":"Myelodysplastic Syndromes, Adult","enrollment":40},{"nctId":"NCT03238248","phase":"PHASE2","title":"Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-08-07","conditions":"Myelodysplastic Syndromes, Myeloproliferative Neoplasm","enrollment":71},{"nctId":"NCT06471946","phase":"PHASE1, PHASE2","title":"VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS","status":"RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-10-01","conditions":"Higher-risk Myelodysplastic Syndromes","enrollment":54},{"nctId":"NCT06598384","phase":"PHASE2","title":"VA as Maintenance Therapy Post Allo-HSCT in MDS and AML","status":"NOT_YET_RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-09","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT03814005","phase":"PHASE1","title":"A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-07-10","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute","enrollment":17},{"nctId":"NCT03530683","phase":"PHASE1","title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-05-14","conditions":"Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia","enrollment":189},{"nctId":"NCT06578546","phase":"PHASE2","title":"Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-02-01","conditions":"Ph-Positive Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT06470841","phase":"PHASE2","title":"CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-09-20","conditions":"Acute Myeloid Leukemia","enrollment":85},{"nctId":"NCT06550713","phase":"PHASE1","title":"A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-10-22","conditions":"Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":100},{"nctId":"NCT06532058","phase":"PHASE2","title":"Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Changzhou Qianhong Bio-pharma Co., Ltd.","startDate":"2023-08-10","conditions":"Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)","enrollment":53},{"nctId":"NCT06301425","phase":"NA","title":"MRD Response-adapted Allo-HSCT for Adverse-risk AML","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-05-24","conditions":"Acute Myeloid Leukemia","enrollment":178}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Subcutaneous azacitidine","genericName":"Subcutaneous azacitidine","companyName":"Otsuka Australia Pharmaceutical Pty Ltd","companyId":"otsuka-australia-pharmaceutical-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferase enzymes, leading to increased expression of tumor suppressor genes. Used for Treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}